Onconetix, Inc. (ONCO) — SEC Filings

Latest SEC filings for Onconetix, Inc. (ONCO), explained in plain English.

Sentiment Overview: 11 bearish, 38 neutral, 1 mixed

Recent Filings (50)

• 425 Filing — 425 · 2026-04-02T08:31:13-04:00 [neutral]
• 425 Filing — 425 · 2026-03-31T09:30:33-04:00 [neutral]
• Onconetix 8-K Signals Potential Leadership/Comp Changes — 8-K · 2026-03-24T17:20:00-04:00 [neutral]
  Onconetix, Inc. filed an 8-K on March 24, 2026, reporting events from March 18, 2026, under Item 5.02, which typically covers changes in directors or officers a
• Onconetix Shifts Focus to Prostate Cancer Diagnostic, Dumps BPH Drug — S-1/A · 2025-12-22T00:00:00.000Z [bearish] Risk: high
  Onconetix, Inc. (ONCO) filed an S-1/A on December 22, 2025, registering 29,778,195 shares of common stock for resale by Selling Stockholders. This includes up t
• Onconetix, Inc. Files Material Definitive Agreement — 8-K · 2025-12-10T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. (formerly Blue Water Biotech, Inc.) entered into a material definitive agreement on December 6, 2025. The company, incorporated in Delaware with
• Onconetix Plunges Deeper into Red Amidst Revenue Collapse, Goodwill Hit — 10-Q · 2025-11-13T00:00:00.000Z [bearish] Risk: high
  Onconetix, Inc. reported a significant net loss of $19,702,029 for the nine months ended September 30, 2025, a decrease from the $29,252,681 net loss in the pri
• Onconetix Seeks Shareholder Nod for Key Capital Raises, Board Appointments — DEF 14A · 2025-11-10T00:00:00.000Z [mixed] Risk: medium
  Onconetix, Inc. (ONCO) is holding its Annual Meeting on December 5, 2025, to address several critical proposals impacting its governance and capital structure.
• Onconetix Registers 22M Shares for Resale, Shifts Focus to Prostate Cancer Diagnostic — S-1 · 2025-11-04T00:00:00.000Z [bearish] Risk: high
  Onconetix, Inc. (ONCO) filed an S-1 on November 4, 2025, registering 22,071,891 shares of common stock for resale by Selling Stockholders. This includes up to 1
• Onconetix, Inc. Reports Shareholder Nomination Event — 8-K · 2025-10-29T00:00:00.000Z [neutral] Risk: low
  Onconetix, Inc. filed an 8-K on October 29, 2025, reporting a shareholder nomination event that occurred on October 23, 2025. The company, formerly known as Blu
• Onconetix Pivots to Prostate Cancer Dx, Dumps BPH Drug Amid ELOC Dilution — S-1 · 2025-10-16T00:00:00.000Z [bearish] Risk: high
  Onconetix, Inc. (ONCO) filed an S-1 on October 15, 2025, primarily to register 5,100,000 shares of common stock for resale by Keystone Capital Partners, LLC, st
• Onconetix, Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · 2025-10-03T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. reported on October 3, 2025, regarding events that occurred on October 1, 2025. The filing indicates an entry into a material definitive agreeme
• Onconetix, Inc. Reports Material Agreement Changes & Equity Sales — 8-K · 2025-09-26T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. filed an 8-K on September 26, 2025, reporting on events that occurred on September 22, 2025. The filing indicates an entry into and termination
• Onconetix, Inc. Files 8-K for Material Agreement — 8-K · 2025-09-22T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. filed an 8-K on September 22, 2025, reporting a material definitive agreement entered into on September 17, 2025. The filing also includes Regul
• Onconetix, Inc. Reports Material Agreement and Financial Obligation — 8-K · 2025-09-04T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. filed an 8-K on September 4, 2025, reporting a material definitive agreement and a direct financial obligation. The filing date of the earliest
• Onconetix Revenue Plummets 85% Amid Strategic Shift, Cash Dwindles — 10-Q · 2025-08-14T00:00:00.000Z [bearish] Risk: high
  Onconetix, Inc. (ONCO) reported a significant decline in revenue and increased net loss for the six months ended June 30, 2025, compared to the same period in 2
• Onconetix, Inc. Files 8-K: Agreements, Financial Obligations, and Officer Changes — 8-K · 2025-08-12T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. announced on August 12, 2025, that it entered into a material definitive agreement on August 6, 2025. The company also reported the creation of
• Onconetix, Inc. Files 8-K with Material Agreements and Officer Changes — 8-K · 2025-07-16T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. filed an 8-K on July 16, 2025, reporting on several key events. These include entering into a material definitive agreement, changes in director
• Onconetix, Inc. Files 8-K with Regulatory Updates — 8-K · 2025-06-16T00:00:00.000Z [neutral] Risk: low
  Onconetix, Inc. filed an 8-K on June 16, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Blue W
• Onconetix Files 10-Q, Maintains Emerging Growth Status — 10-Q · 2025-06-12T00:00:00.000Z [neutral] Risk: high
  Onconetix, Inc. (ONCO) filed its 10-Q for the quarter ended March 31, 2025, indicating its status as a non-accelerated filer, a smaller reporting company, and a
• Onconetix, Inc. Files 8-K on Material Agreement — 8-K · 2025-06-11T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. filed an 8-K on June 11, 2025, reporting a material definitive agreement and a direct financial obligation. The company, formerly known as Blue
• Onconetix, Inc. Files 8-K on Shareholder Votes and Financials — 8-K · 2025-06-05T00:00:00.000Z [neutral] Risk: low
  Onconetix, Inc. filed an 8-K on June 5, 2025, reporting on matters submitted to a vote of security holders and financial statements as of May 30, 2025. The comp
• Onconetix Files 10-K, Confirms Compliance as Smaller Reporting Company — 10-K · 2025-06-02T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. reported its 10-K for the fiscal year ended December 31, 2024, indicating its status as a non-accelerated filer and a smaller reporting company.
• Onconetix, Inc. Files 8-K: Material Agreement, Financial Obligation, Delisting Notice — 8-K · 2025-05-22T00:00:00.000Z [neutral] Risk: high
  Onconetix, Inc. filed an 8-K on May 22, 2025, reporting a material definitive agreement, a direct financial obligation, and a notice of delisting or failure to
• Onconetix Faces Delisting Concerns — 8-K · 2025-04-30T00:00:00.000Z [bearish] Risk: high
  Onconetix, Inc. filed an 8-K on April 30, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as B
• Onconetix Faces Delisting Concerns — 8-K · 2025-04-18T00:00:00.000Z [bearish] Risk: high
  Onconetix, Inc. (formerly Blue Water Biotech, Inc.) filed an 8-K on April 18, 2025, reporting a notice of delisting or failure to satisfy a continued listing ru
• Onconetix, Inc. Files 8-K Report — 8-K · 2025-04-08T00:00:00.000Z [neutral] Risk: low
  Onconetix, Inc. filed an 8-K on April 8, 2025, reporting other events and financial statements. The company, formerly known as Blue Water Biotech, Inc. and Blue
• Onconetix, Inc. Files 8-K on Officer/Director Changes — 8-K · 2025-04-03T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. filed an 8-K on April 3, 2025, reporting on events that occurred on March 28, 2025. The filing pertains to the departure of directors or certain
• Onconetix, Inc. Files 8-K: Standard Disclosure — 8-K · 2025-03-24T00:00:00.000Z [neutral] Risk: low
  Onconetix, Inc. filed an 8-K on March 24, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Blue
• Onconetix, Inc. Files 8-K for Disclosure and Exhibits — 8-K · 2025-03-19T00:00:00.000Z [neutral] Risk: low
  Onconetix, Inc. filed an 8-K on March 19, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Blue
• Onconetix Announces Material Agreement and Officer Changes — 8-K · 2025-02-28T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. announced on February 24, 2025, the entry into a material definitive agreement and changes in its board and officer composition. The company als
• Onconetix, Inc. Files 8-K: Agreements, Financial Obligations, and Personnel Changes — 8-K · 2025-02-18T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. (formerly Blue Water Biotech, Inc.) announced on February 12, 2025, a material definitive agreement and a direct financial obligation. The compa
• Onconetix, Inc. Files S-1/A Amendment — S-1/A · 2025-02-07T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. filed an S-1/A amendment on February 7, 2025, for its initial public offering. The company, formerly known as Blue Water Biotech, Inc. and Blue
• Onconetix, Inc. Files for Public Offering — S-1 · 2025-01-27T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. filed an S-1 registration statement on January 27, 2025, for an unspecified amount of securities. The company, formerly known as Blue Water Biot
• Onconetix Faces Delisting Concerns — 8-K · 2025-01-24T00:00:00.000Z [bearish] Risk: high
  Onconetix, Inc. filed an 8-K on January 24, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the effective
• Onconetix, Inc. Files 8-K — 8-K · 2025-01-22T00:00:00.000Z [neutral] Risk: low
  Onconetix, Inc. filed an 8-K on January 22, 2025, reporting an event that occurred on January 15, 2025. The filing is categorized under 'Other Events' and inclu
• Onconetix Faces Delisting Concerns — 8-K · 2024-12-12T00:00:00.000Z [bearish] Risk: high
  Onconetix, Inc. filed an 8-K on December 12, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The company was formerly known
• Onconetix, Inc. Files S-1/A Amendment No. 3 — S-1/A · 2024-12-11T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. (formerly Blue Water Biotech, Inc.) filed an S-1/A amendment on December 11, 2024, for its registration statement. The company, incorporated in
• Onconetix, Inc. Files Q3 2024 10-Q Report — 10-Q · 2024-12-10T00:00:00.000Z [neutral] Risk: low
  Onconetix, Inc. filed its quarterly report for the period ending September 30, 2024. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vacc
• Onconetix, Inc. Files 8-K for Material Agreement — 8-K · 2024-12-03T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. (formerly Blue Water Biotech, Inc.) entered into a material definitive agreement on November 26, 2024. The filing does not disclose the specific
• SC 13G Filing — SC 13G · 2024-11-14T00:00:00.000Z [neutral]
• Onconetix, Inc. Files S-1/A Amendment for IPO — S-1/A · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. filed an S-1/A amendment on November 12, 2024, for its initial public offering. The company, formerly known as Blue Water Biotech, Inc. and Blue
• Onconetix, Inc. Files S-1 Registration Statement — S-1 · 2024-11-01T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. filed an S-1 registration statement on November 1, 2024, to register securities under the Securities Act of 1933. The company, formerly known as
• Onconetix, Inc. Reports Change in Certifying Accountant — 8-K · 2024-10-21T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. (formerly Blue Water Biotech, Inc.) filed an 8-K on October 21, 2024, reporting a change in its certifying accountant as of October 15, 2024. Th
• Onconetix Delisted from Nasdaq, Files 8-K/A Amendment — 8-K/A · 2024-10-09T00:00:00.000Z [bearish] Risk: high
  Onconetix, Inc. filed an amendment (8-K/A) on October 9, 2024, to its Form 8-K dated September 18, 2024. This amendment primarily addresses the company's failur
• Onconetix, Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · 2024-10-03T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. (formerly Blue Water Biotech, Inc.) entered into a material definitive agreement on October 2, 2024. The company also disclosed unregistered sal
• Ralph Schiess Files SC 13D for Onconetix, Inc. — SC 13D · 2024-10-01T00:00:00.000Z [neutral] Risk: medium
  Ralph Schiess filed an SC 13D on October 1, 2024, regarding Onconetix, Inc. (formerly Blue Water Biotech, Inc. and Blue Water Vaccines Inc.). The filing indicat
• Altos Venture AG Files SC 13D for Onconetix, Inc. — SC 13D · 2024-09-26T00:00:00.000Z [neutral] Risk: medium
  Altos Venture AG, a company based in Allschwil, Switzerland, has filed a Schedule 13D on September 26, 2024, indicating a change in beneficial ownership of Onco
• SC 13G Filing — SC 13G · 2024-09-26T00:00:00.000Z [neutral]
• Onconetix Faces Delisting Concerns — 8-K · 2024-09-24T00:00:00.000Z [bearish] Risk: high
  Onconetix, Inc. filed an 8-K on September 24, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company previously opera
• Onconetix, Inc. Files 8-K for Security Holder Rights Changes — 8-K · 2024-09-20T00:00:00.000Z [neutral] Risk: medium
  Onconetix, Inc. filed an 8-K on September 20, 2024, reporting material modifications to security holder rights and amendments to its articles of incorporation o